AbbVie’s Imbruvica patent win sets up solid growth path after Humira’s decline: analyst
Don’t sleep on AbbVie’s recent federal court victory which upheld its patents on big-selling cancer drug Imbruvica, warns one influential biopharma analyst.
In the c...
Continue Reading →
